Published in Somat Cell Mol Genet on November 01, 1987
Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol (1989) 1.27
Chromosomal destabilization during gene amplification. Mol Cell Biol (1990) 1.07
Evolution and stability of chromosomal DNA coamplified with the CAD gene. Mol Cell Biol (1989) 1.05
The p53 network. J Biol Chem (1998) 3.19
Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci U S A (1996) 2.66
Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesin with drug resistance and cell immortalization. Proc Natl Acad Sci U S A (1994) 1.93
Direct extracellular contact between integrin alpha(3)beta(1) and TM4SF protein CD151. J Biol Chem (2000) 1.69
Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A (1993) 1.60
Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene (2011) 1.26
Chromosome changes caused by alterations of p53 expression. Mutat Res (1996) 1.22
11q deletions in human colorectal carcinomas: cytogenetics and restriction fragment length polymorphism analysis. Genes Chromosomes Cancer (1993) 1.05
Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 3. Inhibitory effect of SkQ1 on tumor development from p53-deficient cells. Biochemistry (Mosc) (2008) 1.04
Disruption of actin microfilaments by cytochalasin D leads to activation of p53. FEBS Lett (1998) 1.00
Multiple mechanisms of N-phosphonacetyl-L-aspartate resistance in human cell lines: carbamyl-P synthetase/aspartate transcarbamylase/dihydro-orotase gene amplification is frequent only when chromosome 2 is rearranged. Proc Natl Acad Sci U S A (1997) 0.95
Activation of p53-mediated cell cycle checkpoint in response to micronuclei formation. J Cell Sci (1998) 0.94
P53-dependent effects of RAS oncogene on chromosome stability and cell cycle checkpoints. Oncogene (1999) 0.94
p53 does not control the spindle assembly cell cycle checkpoint but mediates G1 arrest in response to disruption of microtubule system. Cell Biol Int (1999) 0.93
p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling. Oncogene (2001) 0.93
Multidrug-resistance phenotype of a subpopulation of T-lymphocytes without drug selection. Exp Cell Res (1989) 0.92
Inefficient growth arrest in response to dNTP starvation stimulates gene amplification through bridge-breakage-fusion cycles. Mol Biol Cell (1996) 0.91
Regulation and mechanisms of gene amplification. Philos Trans R Soc Lond B Biol Sci (1995) 0.91
p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Lett (2008) 0.91
Genetic suppressor elements: new tools for molecular oncology--thirteenth Cornelius P. Rhoads Memorial Award Lecture. Cancer Res (1995) 0.90
Specific karyotypic alterations in colchicine-resistant cells. Cytogenet Cell Genet (1981) 0.86
[Effect of on various cell lines of p53 cDNA, expressed under the control of an exogenous homologous promotor]. Mol Biol (Mosk) (1995) 0.86
Cell-specific effects of RAS oncogene and protein kinase C agonist TPA on P-glycoprotein function. FEBS Lett (1995) 0.86
Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53. Gene Ther (2004) 0.86
[Functional heterogeneity of p53-responsive elements]. Mol Biol (Mosk) (1996) 0.85
Karyotype peculiarities of human colorectal adenocarcinomas. Hum Genet (1991) 0.85
Gene amplification in Djungarian hamster cell lines possessing decreased plasma membrane permeability for colchicine and some other drugs. Chromosoma (1985) 0.82
Altered expression of ubiquitous kinesin heavy chain results in resistance to etoposide and hypersensitivity to colchicine: mapping of the domain associated with drug response. Cancer Res (1998) 0.81
Comparison of mitostatic effect, cell uptake and tubulin-binding activity on colchicine and colcemid. Biochim Biophys Acta (1981) 0.81
Colcemid-induced polyploidy and aneuploidy in normal and tumour cells in vitro. Int J Cancer (1975) 0.80
Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells. Oncol Res (1997) 0.79
Regular pattern of karyotypic alterations accompanying gene amplification in Djungarian hamster cells: study of colchicine, adriablastin, and methotrexate resistance. Chromosoma (1985) 0.79
[The protective role of p53 in Ras-induced transformation of REF52 cells]. Mol Biol (Mosk) (2003) 0.79
[Effect of inactivating the p33ING1 tumor suppressor on the function of cell cycle "checkpoints" and genome stability]. Genetika (2000) 0.78
[The human adenosine deaminase gene contains a p53-responsive element]. Dokl Akad Nauk (1996) 0.77
[Hyperproduction of a specific protein in cells resistant to colchicine and adriablastin]. Biull Eksp Biol Med (1983) 0.77
[Construction of chimeric tumor suppressor p53 resistant to the dominant-negative interaction with p53 mutants]. Mol Biol (Mosk) (2002) 0.76
Decreased sensitivity of multidrug-resistant tumor cells to cisplatin is correlated with sorcin gene co-amplification. Neoplasma (1995) 0.76
Application of percolation theory principles to the analysis of interaction of adenylate cyclase complex proteins in cell membranes. Mol Cell Biochem (1988) 0.76
A simple metabolic system for selection of hybrid hybridomas (tetradomas) producing bispecific monoclonal antibodies. Mol Immunol (1988) 0.76
[Mutation of p53 is necessary for stable transformation of REF52 cells by myc+ras oncogenes]. Mol Biol (Mosk) (2000) 0.76
Interaction of proteins of the adenylate cyclase complex: area-limited mobility or movement along the whole membrane? Analysis with the application of the percolation theory. Biosci Rep (1984) 0.76
[Identification of genes activated by mutant forms of p53]. Mol Biol (Mosk) (2000) 0.75
[Multiple drug resistance and differentiation in the population of transformed dog kidney cells MDCK]. Mol Gen Mikrobiol Virusol (1990) 0.75
[Percolation threshold for the lateral displacement of membrane proteins of the adenylate cyclase complex]. Dokl Akad Nauk SSSR (1984) 0.75
[Changes in the genotype and phenotype determining the resistance of Djungarian hamster somatic cells to adriablastin]. Biull Eksp Biol Med (1983) 0.75
[Effects of various mutant p53 on the sensitivity of cells to cytostatics]. Biull Eksp Biol Med (1999) 0.75
[Specific karyotype changes in cells resistant to colchicine]. Genetika (1981) 0.75
[Relation of mammalian cell resistance to actinomycin D with a change in the karyotype and a decrease in cytoplasmic membrane permeability]. Genetika (1981) 0.75
[The effect of the tumor suppressor p53 and its mutant forms on the differentiation and viability of K562 leukemic cells]. Tsitologiia (1996) 0.75
[Genetic study of the resistance of mouse somatic cells to colchicine (high resistance level)]. Genetika (1979) 0.75
A study of mechanisms of post-irradiation changes in adenylate-cyclase activity. Int J Radiat Biol Relat Stud Phys Chem Med (1983) 0.75
[Relationship between amplicon composition and cytologic type of structures containing amplified DNA in murine P388 cells with multiple drug resistance]. Genetika (1995) 0.75
[Effect of some drugs on colchicine uptake by colchicine-sensitive and resistant cells]. Biull Eksp Biol Med (1979) 0.75
[Hormone-dependent process of the maturation of the major structural proteins of the mouse mammary tumor virus]. Vopr Virusol (1982) 0.75
[Progress in understanding moleculr mechanisms of oncogenesis, and novel methods of tumor growth control]. Vestn Ross Akad Med Nauk (2007) 0.75
[Genetic analysis of the resistance of mouse somatic cells to colchicine]. Genetika (1978) 0.75
Effects of radioprotectors on the cAMP and cGMP systems. Radiat Environ Biophys (1984) 0.75
[Pattern of evolution of amplicons during the development of multiple drug resistance in Djungarian hamster cells]. Mol Gen Mikrobiol Virusol (1987) 0.75
[Priorities in research of hemoblastosis]. Vestn Ross Akad Med Nauk (1999) 0.75
Depression of the radioprotective effect of isoproterenol on mammalian cells in vitro after desensitization of the cAMP system. Int J Radiat Biol Relat Stud Phys Chem Med (1985) 0.75
[Increased tendency to chromosome nondisjunction arising as a result of Robertsonian translocations]. Genetika (1974) 0.75
[Characteristics of the karyotype changes in Djungarian hamster cells resistant to methotrexate]. Genetika (1983) 0.75
[Dominant-negative inactivation of p53: the effect of the proportion between trans-dominant inhibitor and its target]. Mol Biol (Mosk) (2003) 0.75
[Stimulation of differentiation of LIM 1215 large intestinal tumor cells during expression of the p53 exogenous antioncogene or the activated ras oncogene]. Arkh Patol (1996) 0.75
[Genome instability and oncogenesis]. Mol Biol (Mosk) (2007) 0.75
[Role of the nucleus and the cytoplasm in determining the change in the permeability for colchichine of the plasma membrane of mouse cells]. Genetika (1982) 0.75
[Chromosomal and extrachromosomal localization of amplified genes in colchicine-resistant cells]. Dokl Akad Nauk SSSR (1982) 0.75
[Endogenous MMTV in the normal mammary gland and in dimethylanthracene-induced mammary cancer in BALB/c mice]. Mol Gen Mikrobiol Virusol (1987) 0.75
[Genetic study of stable inheritable cell resistance to colchicine. Chromosomal and hybridization analysis]. Genetika (1982) 0.75
[Mouse cell line with stable inheritance of colchicine resistance]. Biull Eksp Biol Med (1981) 0.75
[Amplification of genome regions in the somatic cells of mammals resistant to colchicine. III. Localization of the amplified genes in minute chromatin bodies]. Genetika (1982) 0.75
[Dependence of hormonal stimulation of adenylate cyclase on the fraction of plasma membrane accessible to the lateral transport of adenylate cyclase complex proteins]. Biokhimiia (1986) 0.75
[Opposite effect of p53 on nucleotide metabolizing enzyme activity in Rat1 cells and their sublines, transformed by N-RAS or v-mos oncogenes]. Biokhimiia (1995) 0.75
[Gene amplification in murine leukemia cells with multiple drug resistance acquired in vivo]. Genetika (1987) 0.75
Molecular characterization of the breakpoint region associated with a constitutional t(2;15)(q34;q26) in a patient with multiple myeloma. Cancer Genet Cytogenet (2001) 0.75
[Amplification of portions of the genome in mammalian somatic cells resistant to colchicine. VI. Restriction analysis of the amplified DNA sequences]. Genetika (1983) 0.75
[Induction of gene amplification in Djungarian hamster cells by various chemical carcinogens]. Biull Eksp Biol Med (1986) 0.75
[Effect of inactivating various components of the signal pathways of the tumor suppressor p53 on genomic stability]. Genetika (1999) 0.75
Newly formed chromosome-like structures in independent mouse P388 sublines with developed in vivo mdr1 gene amplification. Somat Cell Mol Genet (1991) 0.75
[Cloning and characteristics of DNA sequences amplified in Djungarian hamster cells with multidrug resistance]. Mol Gen Mikrobiol Virusol (1987) 0.75
[Isolation of DNA probes for the detection of sequences amplified in colchicine-resistant cells]. Mol Biol (Mosk) (1986) 0.75
[The outpatient management of patients with a transplanted kidney]. Ter Arkh (1990) 0.75
Selective protection of cells against X-irradiation. Isoproterenol protects only those cells that possess beta-adrenoreceptors. Experientia (1985) 0.75
[New Djungarian hamster cell lines with selective cytoplasmic and nuclear genetic markers]. Genetika (1982) 0.75
[Characteristics of A-type intracytoplasmic particles produced by human cells]. Biull Eksp Biol Med (1981) 0.75
[Desensitization of beta-adrenoreceptors and its influence on manifestations of the antiradiation effect of isoproterenol]. Biull Eksp Biol Med (1984) 0.75
[Oncogenes, antioncogenes and carcinogenesis]. Arkh Patol (1990) 0.75